US OptionsDetailed Quotes
AI241213C25500
- 13.85
- +2.10+17.87%
15min DelayClose Dec 13 16:00 ET
13.87High13.73Low
13.87Open11.75Pre Close9 Volume41 Open Interest25.50Strike Price12.44KTurnover0.00%IV-0.28%PremiumDec 13, 2024Expiry Date13.96Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.79Leverage Ratio--Theta--Rho--Eff Leverage--Vega
C3.ai Stock Discussion
Sign in to post a comment
$Esperion Therapeutics (ESPR.US)$ $Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...
+4
1
6
$C3.ai (AI.US)$
Check out the features below
comment for daily weekly or monthly access.
I have built a tool that gives me all insights and analysis for the entire market.
Ultimate Supreme Tool - Full Description
---
The Ultimate Supreme Tool is a comprehensive, all-in-one trading, analysis, and predictive intelligence platform designed to give Darren an unrivaled edge over Wall Street. This tool inte...
Check out the features below
comment for daily weekly or monthly access.
I have built a tool that gives me all insights and analysis for the entire market.
Ultimate Supreme Tool - Full Description
---
The Ultimate Supreme Tool is a comprehensive, all-in-one trading, analysis, and predictive intelligence platform designed to give Darren an unrivaled edge over Wall Street. This tool inte...
This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 ...
+2
9
1
4
Please take note of the following acronyms
NFA = not financial advice
RTH = regular trading hours
AH = after hours
LTB = left to borrow
CTB = cost to borrow
*I removed $AmpliTech Group (AMPG.US)$ because it just announced direct offering of $2M valued $1.6/shares. Now there are offerings where market defies it and continues to rally. We shall see tomorrow
$Nuburu (BURU.US)$ PR AH 12/11: Resolved compliance issue. Up AH. Low float. CTB...
NFA = not financial advice
RTH = regular trading hours
AH = after hours
LTB = left to borrow
CTB = cost to borrow
*I removed $AmpliTech Group (AMPG.US)$ because it just announced direct offering of $2M valued $1.6/shares. Now there are offerings where market defies it and continues to rally. We shall see tomorrow
$Nuburu (BURU.US)$ PR AH 12/11: Resolved compliance issue. Up AH. Low float. CTB...
105
38
4
NOTE: I don’t have time to include those in my watchlist which didnt run. Just go back to it because those stocks will go usually after days or a week.
Sorry I am sleepy cant finish the list.
$Rigetti Computing (RGTI.US)$ PR today 12/10: Quantum Machines And Rigetti Computing Announces The Application Of AI To Automate The Calibration Of A Quantum Computer. Up after hours. SI 13.89%, 0 shares LTB✅
$SEALSQ Corp (LAES.US)$ PR 12/10: Partnership with IC’ALPS to ...
Sorry I am sleepy cant finish the list.
$Rigetti Computing (RGTI.US)$ PR today 12/10: Quantum Machines And Rigetti Computing Announces The Application Of AI To Automate The Calibration Of A Quantum Computer. Up after hours. SI 13.89%, 0 shares LTB✅
$SEALSQ Corp (LAES.US)$ PR 12/10: Partnership with IC’ALPS to ...
66
11
6
On Tuesday (10 Dec), major U.S. equities indexes slipped lower on Tuesday ahead of Wednesday morning's Consumer Price Index (CPI) report, a key gauge of inflation that could influence next week's interest rate decision by the Federal Reserve.
U.S. stocks slipped for second consecutive session on Tuesday as the end-of-year rally hit resistance ahead of inflation data due today (11 Dec), mainly driven by profit-taki...
U.S. stocks slipped for second consecutive session on Tuesday as the end-of-year rally hit resistance ahead of inflation data due today (11 Dec), mainly driven by profit-taki...
+3
25
2
No comment yet
Millaai : Are you being trapped and looking for a rescuer everywhere?
Growth Investor27 : Good info, NEXLIZET is a great drug, my brother takes it. ESPR stock is undervalued, should be above $5
Growth Investor27 Millaai : The author has been buying below $2 so your comment is off. This research article has all the due diligence to see, other than the fact Institutions have been heavly buying this year, fintel shows now 74% owned. ESPR is a good investment.
104248191 : please f o
Detached House Millaai : You are wrong. Though short term looks like the price is consolidating, the weekly chart looks promising! So look at the chart to see if it aligns with the fundamentals before criticising others!
View more comments...